BioLife Solutions Expands Product Portfolio with Qkine Partnership

2026-02-12 09:30:51 ET

BioLife Solutions, Inc. (NASDAQ: BLFS) , a top provider of bioproduction tools for the cell and gene therapy (CGT) market, has signed a multi-year supply agreement with Qkine Limited. This deal allows BioLife to distribute Qkine's cytokine and growth factor products, further expanding its offerings in the fast-growing cytokines market.

Exclusive Distribution and Collaboration on Packaging Innovation

The agreement grants BioLife exclusive global distribution rights to specific Qkine products for CGT applications, along with non-exclusive rights to others. Additionally, the companies will collaborate on process development to package Qkine's products using BioLife's proprietary CellSeal(R) Connect vial system. This innovative system integrates into closed and automated CGT workflows, enhancing efficiency and reliability.

Leadership Perspectives on the Partnership

Roderick de Greef, BioLife's Chairman and CEO, emphasized the strategic value of the partnership. "This strategic relationship with Qkine strengthens our portfolio and aligns with our growth strategy. Cytokines are a natural fit with our cell culture supplements and represent a fast-growing, profitable market," he said.

Dr. Robert Scoffin, Qkine's CEO, shared his excitement. "Partnering with BioLife combines our expertise in cytokine innovation with their strong market presence. Together, we'll deliver more value to customers and advance next-generation cell and gene therapies," he stated.

Cytokines: A Growing Market Opportunity

Cytokines and growth factors play a critical role in CGT manufacturing by regulating and stimulating cell growth and performance. According to market research, the global cytokines market is valued at $500 million annually and is projected to double by 2030, driven by expanding CGT development pipelines.

Advancing Innovation and Growth

This partnership underscores BioLife's commitment to innovation and growth. By teaming up with Qkine, BioLife enhances its product portfolio and strengthens its role in advancing CGT development.

About Qkine Limited
Headquartered in Cambridge, England, Qkine Limited is at the forefront of advancing stem cell and regenerative medicine research. The company specializes in developing high-purity, bioactive growth factors and cytokines, with a strong emphasis on scientific rigor and product excellence. Qkines mission is to support cutting-edge biological research and clinical translation worldwide. For more information, visit www.qkine.com .

About BioLife Solutions
BioLife Solutions is a leading developer and supplier of bioproduction products and services tailored for the cell and gene therapy (CGT) and broader biopharma markets. The company's expertise lies in facilitating the commercialization of new therapies by providing solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, visit www.biolifesolutions.com .

The post BioLife Solutions Expands Product Portfolio with Qkine Partnership appeared first on PRISM MarketView .

COMTEX_473395157/2927/2026-02-12T09:30:51